Key result
Intrapleural perfusion with hyperthermic chemotherapy achieved a 100% total response rate (71.3% complete response) and a median survival of 16.8 months in patients with malignant pleural effusions.
Why the study?
Does intrapleural perfusion with hyperthermic chemotherapy improve treatment response in patients with malignant pleural effusions?
Observational (n=80)
Does intrapleural perfusion with hyperthermic chemotherapy improve treatment response in patients with malignant pleural effusions?
Intrapleural perfusion with hyperthermic chemotherapy under video-assisted thoracoscopic surgery is a safe and effective approach for managing malignant pleural effusions, providing a 100% response rate and survival benefit.
Supports further investigation of hyperthermic perfusion; should not yet change practice pending randomized confirmation.
BACKGROUND: Patients with malignant pleural effusions (MPEs) have limited life expectancy. This study aims to investigate the feasibility of intrapleural perfusion with hyperthermic chemotherapy (IPHC) under video-assisted thoracoscopic surgery on MPE patients. METHODS: MPE patients were enrolled in the study and treated with IPHC. The treatment response was classified as complete response (CR, no re-accumulation of pleural fluid for 4 weeks), partial response (PR, re-accumulation above the post-IPHC level but below the pre-IPHC level for four weeks), no response (NR; re-accumulation or above the pre-IPHC level). The change of Karnofsky performance score (KPS) and tumour markers were also recorded. Follow-up was done every two weeks during first month and monthly thereafter until death. RESULTS: Eighty patients included 46 males and 34 females were included in the study. The total response rate was 100%, with 71.3% of CR and 28.7% of PR. The KPS scores were significantly elevated and the level of tumour markers in pleural effusion were dramatically decreased after IPHC. The median survival was 16.8 months ranged from 2.1 to 67.4 months. One-year and two-year survival rates were 82.5% and 23.8%, respectively. There were no serious clinical compilations during IPHC treatment. CONCLUSIONS: IPHC is a safety, effective and promising approach for MPE patients. It provides well survival benefit and minor toxicities.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2017) conducted an observational in Malignant pleural effusions (n=80). Intrapleural perfusion with hyperthermic chemotherapy (IPHC) under video-assisted thoracoscopic surgery was evaluated on Total response rate. Intrapleural perfusion with hyperthermic chemotherapy achieved a 100% total response rate (71.3% complete response) and a median survival of 16.8 months in patients with malignant pleural effusions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: